Charles River Laboratories International, Inc. completed its initial public offering and began trading its common shares publicly on the New York Stock Exchange under the ticker symbol CRL in June 2000. This milestone followed a management buyout from Bausch & Lomb, allowing the enterprise to transition into an independent publicly traded corporation and subsequently expand its operational capabilities through strategic acquisitions into a comprehensive global contract research organization.